How does 0Q4U's PE Ratio compare to its peers?

0Q4U is expensive based on its Price-To-Earnings Ratio (85.9x) compared to the peer average (25.2x).

How does 0Q4U's PE Ratio compare vs other companies in the European Chemicals Industry?

0Q4U is expensive based on its Price-To-Earnings Ratio (85.9x) compared to the European Chemicals industry average (17.9x).

What is 0Q4U's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0Q4U is expensive based on its Price-To-Earnings Ratio (85.9x) compared to the estimated Fair Price-To-Earnings Ratio (15.8x).

What is the Fair Price of 0Q4U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0Q4U (DKK390.1) is trading below our estimate of [[fair value]] (DKK395.97)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Novonesis (LSE:0Q4U) - Stock Price, News & Analysis

0Q4U Stock Overview

Produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. More details

0Q4U fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 1.5% below our estimate of its fair value

Analysts in good agreement that stock price will rise by 24.8%

Risk Analysis

Shareholders have been substantially diluted in the past year

Large one-off items impacting financial results

Profit margins (9.3%) are lower than last year (19.3%)

Novonesis A/S Competitors

Croda International

LSE:CRDA

UK£4.8b

Johnson Matthey

LSE:JMAT

UK£2.6b

Victrex

LSE:VCT

UK£749.6m

Treatt

LSE:TET

UK£256.6m

Price History & Performance

Summary of all time highs, changes and price drops for Novonesis
Historical stock prices
Current Share Price	DKK 390.10
52 Week High	DKK 547.40
52 Week Low	DKK 335.00
Beta	0.54
11 Month Change	-13.66%
3 Month Change	-12.36%
1 Year Change	7.96%
33 Year Change	-24.95%
5 Year Change	20.18%
Change since IPO	312.45%

Recent updates

Shareholder Returns

	0Q4U	GB Chemicals	GB Market
7D	-8.5%	-3.9%	-0.4%
1Y	8.0%	-18.2%	5.6%

Return vs Industry: 0Q4U exceeded the UK Chemicals industry which returned -18.2% over the past year.

Return vs Market: 0Q4U exceeded the UK Market which returned 5.6% over the past year.

Price Volatility

Is 0Q4U's price volatile compared to industry and market?
0Q4U volatility
0Q4U Average Weekly Movement	2.8%
Chemicals Industry Average Movement	5.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0Q4U has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0Q4U's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	10,452	Ester Baiget	www.novonesis.com

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novonesis A/S Fundamentals Summary

How do Novonesis's earnings and revenue compare to its market cap?
0Q4U fundamental statistics
Market cap	DKK 181.25b
Earnings (TTM)	DKK 2.11b
Revenue (TTM)	DKK 22.71b

85.9x

P/E Ratio

8.0x

P/S Ratio

Is 0Q4U overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0Q4U income statement (TTM)
Revenue	€3.04b
Cost of Revenue	€1.62b
Gross Profit	€1.42b
Other Expenses	€1.14b
Earnings	€282.79m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 26, 2025

Earnings per share (EPS)	0.61
Gross Margin	46.66%
Net Profit Margin	9.29%
Debt/Equity Ratio	18.1%

How did 0Q4U perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

108%

Payout Ratio

0Q4U Stock Overview

Rewards

Risk Analysis

Novonesis A/S Competitors

LSE:CRDA

UK£4.8b

LSE:JMAT

UK£2.6b

LSE:VCT

UK£749.6m

LSE:TET

UK£256.6m

Price History & Performance

Recent News & Updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Now 10% overvalued after recent price rise

Now 21% overvalued after recent price rise

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Now 10% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 22% overvalued after recent price rise

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Financial position

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Now 21% undervalued after recent price drop

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.8% yield

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released